Dr. Nagourney's Blog

Email-box.png

Informative articles sent right to your inbox. Subscribe to Dr. Nagourney's blog today.

Robert A. Nagourney, MD

Robert A. Nagourney, MD

Dr. Robert Nagourney has been a pioneer in personalized cancer testing and research for over 20 years. He is founder and director of Nagourney Cancer Institute (formerly Rational Therapeutics), an accomplished research and testing lab in Long Beach, personalizing cancer patient treatments from all over the world. Dr. Nagourney is author of the book Outliving Cancer, blogger, practicing oncologist, and clinical professor at the University of California, Irvine.

Among his many accomplishments, as co-investigator on national cooperative trials, Dr. Nagourney is recognized for the introduction of Cisplatin/Gemcitabine doublets in the treatment of advanced ovarian and breast cancers. Also, Dr. Nagourney's group originally reported the effectiveness of this same drug combo for advanced bladder cancer at a research symposium in Washington DC, ten years before it became the treatment of choice.

He has been featured on national and local television such as CNN, ABC World News Tonight, CNBC and major newspapers such as the Wall Street Journal. He has also been featured internationally such as on the Australian TV show Good Medicine, and Univision's Primer Impacto.

He has also served as a reviewer and on the editorial boards of several journals including Clinical Cancer Research, British Journal of Cancer, Gynecologic Oncology, Cancer Research and the Journal of Medicinal Food.

Follow Dr. Nagourney on Twitter @RobertNagourney
Find me on:

Recent Posts

For a 26-year-old Stage 4 Adrenal Cancer: It's Knowing Where (and How) to Look
By Robert A. Nagourney, MD
“When you have eliminated the impossible, whatever remains, however improbable, must be the truth” Sherlock Holmes The Sign of...
Serendipity Saves a Life for a Patient with Advanced Breast Cancer
By Robert A. Nagourney, MD
In early September of 2018, I consulted with a 51-year-old patient with heavily pre-treated, extremely advanced metastatic...
For Some Cancers Are There Immunotherapy Hazards?
By Robert A. Nagourney, MD
A report by French investigators has raised concern regarding the broad application of immunotherapy in lung cancer. Checkpoint...
Cancer, Computers and Genes: A Bad Mix for Patients
By Robert A. Nagourney, MD
Every day, we hear of another breakthrough using gene testing and DNA to identify a new target, new treatment, new combination...
High Cost of Cancer Care To 340B or Not To 340B, That Is The Question?
By Robert A. Nagourney, MD
There are many reasons why medical care costs continue to spiral out of control. Some of these are systemic like an aging...
The Right Treatment at the Right Time: Double-Hit Lymphoma
By Robert A. Nagourney, MD
On February 5th, 2018 I was asked to consult on a 53-year-old patient who was admitted to the hospital with a one month’s...
Cancer Patients and the "Right To Try"
By Robert A. Nagourney, MD
On May 30, 2018 the president signed HR 878, granting terminally ill patients the right to try experimental drugs. While there...

most popular articles

patient story

How We Helped David Hanbidge

"I'll never forget the day when the doctor took my wife and me to a small back office and told us the horrible news…I had the very worst kind of lung cancer..."   Read about how we helped David.